Next Article in Journal
Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review
Next Article in Special Issue
Structural and Functional Analysis of Female Sex Hormones against SARS-CoV-2 Cell Entry
Previous Article in Journal
Therapeutic Effect of α-MSH in Primary Cultured Orbital Fibroblasts Obtained from Patients with Thyroid Eye Disease

Long Term Immune Response Produced by the SputnikV Vaccine

IFMIB, Kazan Federal University, 420008 Kazan, Russia
Kazan State Medical Academy, 420012 Kazan, Russia
Department of Infectious Diseases, Kazan State Medical Academy, 420012 Kazan, Russia
Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, India
Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK
Author to whom correspondence should be addressed.
Academic Editor: Alberto Cuesta
Int. J. Mol. Sci. 2021, 22(20), 11211;
Received: 31 August 2021 / Revised: 13 October 2021 / Accepted: 13 October 2021 / Published: 18 October 2021
(This article belongs to the Special Issue COVID-19: Molecular Biology Research)
SputnikV is a vaccine against SARS-CoV-2 developed by the Gamaleya National Research Centre for Epidemiology and Microbiology. The vaccine has been shown to induce both humoral and cellular immune responses, yet the mechanisms remain largely unknown. Forty SputnikV vaccinated individuals were included in this study which aimed to demonstrate the location of immunogenic domains of the SARS-CoV-2 S protein using an overlapping peptide library. Additionally, cytokines in the serum of vaccinated and convalescent COVID-19 patients were analyzed. We have found antibodies from both vaccinated and convalescent sera bind to immunogenic regions located in multiple domains of SARS-CoV-2 S protein, including Receptor Binding Domain (RBD), N-terminal Domain (NTD), Fusion Protein (FP) and Heptad Repeats (HRs). Interestingly, many peptides were recognized by immunized and convalescent serum antibodies and correspond to conserved regions in circulating variants of SARS-CoV-2. This breadth of reactivity was still evident 90 days after the first dose of the vaccine, showing that the vaccine has induced a prolonged response. As evidenced by the activation of T cells, cellular immunity strongly suggests the high potency of the SputnikV vaccine against SARS-CoV-2 infection. View Full-Text
Keywords: SARS-CoV-2; SputnikV; Spike protein; humoral immune response; cellular immunity SARS-CoV-2; SputnikV; Spike protein; humoral immune response; cellular immunity
Show Figures

Figure 1

MDPI and ACS Style

Martynova, E.; Hamza, S.; Garanina, E.E.; Kabwe, E.; Markelova, M.; Shakirova, V.; Khaertynova, I.M.; Kaushal, N.; Baranwal, M.; Rizvanov, A.A.; Urbanowicz, R.A.; Khaiboullina, S.F. Long Term Immune Response Produced by the SputnikV Vaccine. Int. J. Mol. Sci. 2021, 22, 11211.

AMA Style

Martynova E, Hamza S, Garanina EE, Kabwe E, Markelova M, Shakirova V, Khaertynova IM, Kaushal N, Baranwal M, Rizvanov AA, Urbanowicz RA, Khaiboullina SF. Long Term Immune Response Produced by the SputnikV Vaccine. International Journal of Molecular Sciences. 2021; 22(20):11211.

Chicago/Turabian Style

Martynova, Ekaterina, Shaimaa Hamza, Ekaterina E. Garanina, Emmanuel Kabwe, Maria Markelova, Venera Shakirova, Ilsiyar M. Khaertynova, Neha Kaushal, Manoj Baranwal, Albert A. Rizvanov, Richard A. Urbanowicz, and Svetlana F. Khaiboullina. 2021. "Long Term Immune Response Produced by the SputnikV Vaccine" International Journal of Molecular Sciences 22, no. 20: 11211.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop